Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
AMG420
Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- NCT03836053 ↗
- Terminated
- Amgen
- Focused
We haven't built an HCP commentary report on AMG420 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on AMG420 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- AMG 420
- Arms
- AMG 420 · Experimental
- Enrollment
- 23
- Primary outcomes
- Number of Participants With Dose-limiting Toxicities (DLTs)
- Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
- Number of Participants Who Experienced a Treatment-related TEAE
- Sponsor
- Amgen
- Start
- Mar 4, 2019
- Primary completion
- Apr 21, 2022
- Results posted
- Yes
- Registry record
- NCT03836053 · updated Sep 11, 2025
Publications
linked from the registry- Rodriguez C, Rodriguez T, Kentos A, Driessen C, Sunami K, Lesokhin AM, Yee AJ, Minella AC, Maraboina R, Upreti VV, Zhou D, Shabooti M, Stieglmaier J, Quach H. BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study. Leuk Lymphoma. 2025 Nov;66(11):2108-2117. doi: 10.1080/10428194.2025.2528115. Epub 2025 Jul 21. PubMed 40690374